Investing

Israeli study finds Pfizer COVID-19 booster protects against Omicron By Reuters


© Reuters. FILE PHOTO: A health worker prepares a dose of Pfizer/BioNTech’s COVID-19 vaccine, at the Penda health center in Nairobi, Kenya, December 9, 2021. REUTERS/Baz Ratner/File Photo

JERUSALEM (Reuters) – Israeli researchers said on Saturday they found that a three-shot course of the Pfizer/BioNTech COVID-19 vaccine provided significant protection against the new Omicron variant.

The findings were similar to those presented by BioNTech and Pfizer (NYSE:) earlier in the week, which were an early signal that booster shots could be key to protect against infection from the newly identified variant.

The study, carried out by Sheba Medical Center and the Health Ministry’s Central Virology Laboratory (NYSE:), compared the blood of 20 people who had received two vaccine doses 5-6 months earlier to the same number of individuals who had received a booster a month before.

“People who received the second dose 5 or 6 months ago do not have any neutralization ability against the Omicron. While they do have some against the Delta (strain),” Gili Regev-Yochay, director of the Infectious Diseases Unit at Sheba, told reporters.

“The good news is that with the booster dose it increases about a hundred fold. There is a significant protection of the booster dose. It is lower than the neutralization ability against the Delta, about four times lower,” she said.

The Israeli team said they worked with the actual virus while the companies used what is known as a pseudovirus, which was bio-engineered to have the hallmark mutations of Omicron.

The Israeli research follows a study from South Africa that found the Omicron variant can partially evade protection from two doses.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.


Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button